Syngene International Ltd
Syngene International Ltd (SYNGENE)

Syngene International Ltd (SYNGENE)


Key Stats

Day's Price Range
52-Week Price Range
1 Month Return-14.5 %
3 Month Return-2.67 %
1 Year Return-9.09 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

Rank 8
Rank 8
Rank 10
Dividend Yield
Rank 11
Rank 8
Price To Book Ratio
Rank 7
Debt To Asset
Rank 6

Company Information

Syngene International Limited is an internationally reputed custom research and manufacturing organisation which supports RD programs from lead generation to clinical supplies. The company was promoted by Biocon and Kiran Mazumdar Shaw a promoter of Biocon Limited. The company was formed with objectives of providing contract research service to overseas customer in the field of synthetic chemistry molecular biology and custom synthesis. The company provides integrated services to the pharmaceutical biotechnology nutrition animal health consumer goods and specialty chemicals industries across the world. Syngenes clientele include market leaders such as BristolMyers Squibb Baxter Amgen GSK Zoetis Merck KGaA and Herbalife. The company was incorporated at Bangalore in the year 1993. During the year 19941995 the company pioneered in CRO services for both Chemistry and Biology. During the year 20012002 the company acquired a new facility inclusive of a cGMP pilot plant. In March 30 2002 the companys 99.9 equity share was transferred to Biocon and the company became a subsidiary of Biocon Ltd. During the year 20032004 the company introduced Process Research and Optimization Services. In October 21 2004 the company commissioned a new research facility at Boammasandra Bangalore. In February 15 2006 the company commissioned new facility at Biocon Park. In August 30 2006 the company received approval of additional facility to set up as SEZ unit from Cochin Special Economic Zone. During the year 20062007 Bristol Myers Squibb had entered into a long term agreement with the company to set up an exclusive research facility to house more than 400 scientists. During the year the company had ventured into other area of Biology viz Genetic Engineering Protein Chemistry and assay development. The company had developed extensive expertise in the creation of customized stable cell lines expressing proteins / receptors of intersest. During the year 20072008 the company entered a long term service agreement with BMS. During the year 20082009 the company created an alliance partnership with DuPont Crop Protection.On 21 July 2011 Syngene International and Endo Pharmaceuticals USA announced that they have signed an agreement to expand their collaboration to develop novel biological therapeutic molecules against cancer. Syngene and Endo will partner on two new discovery programmes strengthening their ongoing alliance in cancer research. Under the agreement Endo will retain all rights to the molecules developed while Syngene International will receive research fees milestone payments and success fees from Endo.On 4 June 2012 Abbott one of Indias largest healthcare companies inaugurated its first nutrition research and development center in the country in collaboration with Syngene International. The stateoftheart Research and Development center will focus on the development of sciencebased affordable nutrition products for the country and enable the expansion of Abbotts nutrition product portfolio.In 2012 Syngene International received ANVISA Certification of clinical facilities. During the year under review Syngene International acquired 100 stake in Clinigene International Limited from Biocon.Syngene International crossed an annual turnover of Rs 500 crore crore in the year ended 31 March 2013.In 2013 Baxter International Inc. collaborated with Syngene International to establish the Baxter Global Research Center. During the year under review Syngene Internationals Control Testing Laboratory received acceptance from the Department of Health Human Services US Food and Drug Administration.On 3 June 2014 BristolMyers Squibb and Syngene International announced a fiveyear extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.In 2014 Syngene Internationals API manufacturing facility received acceptance from Department of Health Human Services US Food and Drug Administration. During the year under review Syngene International established a 75000 sq. ft. centre to provide stability and analytical services.Syngene International made its debut on the secondary equity market on 11 August 2015. The stock debuted at Rs 295 on BSE a premium of 18 compared to the initial public offer IPO price of Rs 250 per share. The Rs 550crore Initial Public Offering IPO through offer for sale from its parent Biocon Ltd. received an excellent response from investors and was subscribed 32.05 times. The issue opened for subscription on 27 July 2015 and closed on 29 July 2015.In 2015 Syngene Internationals subsidiary Clinigene International Limited which provides clinical research and clinical trial services was amalgamated with Syngene International. Syngene International crossed annual turnover of Rs 1000 crore in the year ended 31 March 2016.On 6 September 2016 Syngene International announced the establishment in Bangalore India of an integrated multidisciplinary drug discovery and development center for Amgen Inc. The stateoftheart dedicated center will be staffed by a team of more than 100 highly qualified Syngene scientists working in close association with Amgen researchers around the world on the discovery and development of innovative medicines. In addition to being customized to meet Amgens functional requirements the facility complies with the highest regulatory standards. Its design includes a range of environmentallyfriendly features and flexible layouts and is configured to minimize solvent and effluent waste with a strong emphasis on laboratory safety and green chemistry.On 21 September 2016 Syngene International Ltd.and Strand Life Sciences announced that they have completed a deal through which Syngene has purchased assets of Strand Life Sciences related to systems biology Heptox and pharma bioinformatics services. This includes target dossier business and rights to NGS data analytics and Sarchitect platforms supported by a strong scientific team. Financial details of the deal were not disclosed. This deal gives Syngene access to Strands patented Virtual Liver model and the NGS analytics platform. The Virtual Liver model is able to predict the toxic effect of different drugs or chemicals on the liver both rat and human using information from laboratorybased experiments prior to actual testing on live animals or humans. Strand NGS is an integrated platform that provides analysis management and visualization tools for nextgeneration sequencing data.On 2 March 2017 Herbalife a global nutrition company announced the launch of its first Nutrition Research and Development Lab in India in partnership with Syngene International. The strategic partnership will help Herbalife Nutrition develop and formulate worldclass nutrition products for Indian consumers.On 27 July 2017 Syngene International announced the expansion of its research collaboration with Amgen Inc. As a result Syngene will expand the Syngene Amgen Research Development Center SARC in terms of size and scope of its operations. The expansion of SARC will be customized to meet Amgens functional requirements and will include a range of environmentfriendly features that will enable optimal utilization of the laboratory space.On 14 November 2017 Syngene International announced that it has expanded its ongoing collaboration with BristolMyers Squibb. The next phase of the partnership will see the addition of a new facility to support future BristolMyers Squibb research and development operations an expansion of the team and the extension of the existing agreement through 2026. As part of the expansion Syngene will set up a new dedicated facility spread across 25000 sq. ft. of laboratory and office space for BristolMyers Squibb. This facility will house an additional team of 75 Syngene scientists who will work exclusively in support of BristolMyers Squibb.On 26 March 2018 Syngene International announced an RD agreement with GSK a scienceled global healthcare company. The multiyear agreement will focus on accelerating the discovery of new drug candidates using Syngenes discovery services platforms. As part of the agreement Syngene will setup a customized discovery research laboratory to support projects across several therapeutic areas. A team of Syngene scientists will work closely with GSKs global RD teams on discovery research projects to identify new drug candidates with the potential to address some of the worlds most pressing healthcare needs.On 30 May 2018 Syngene International announced that the company has entered into a nonexclusive partnering agreement with Zumutor Biologics an emerging immunooncology company to access Zumutors proprietary nave human phage/yeast display library. This collaboration further enhances Syngenes marketleading capabilities in Discovery Biology providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery. Under the terms of the agreement Syngene will screen target antigens against Zumutors proprietary human antibody libraries to identify and characterize novel antibody clones which will be further developed by Syngene towards novel biotherapeutics programs for its partnersOn 23 July 2018 Syngene International Ltd. announced the expansion of the scope of its RD collaboration with Baxter Healthcare Corporation a global healthcare company. As part of the expansion Syngene will set up additional infrastructure at the dedicated Baxter Global Research Center BGRC as well as increase the size of its scientific team working on Baxter projects. The duration of the agreement has also been extended until 2024. Syngene and Baxter originally established the Baxter Global Research Center a dedicated RD center in 2013.
OrganisationSyngene International Ltd